Could a simple device replace the needle for blood tests?
NCT ID NCT06507566
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested a small device called Tasso+™ that collects blood from the upper arm, aiming to make blood draws easier for clinical trials and pandemic monitoring. About 200 healthy adults used the device, and researchers checked if the blood samples were good enough for lab tests. The goal was to see if this device could work outside of hospitals, so people could participate in studies from home.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tasso+™ blood collection device
- What this could lead to
- If successful, this device could allow people to collect blood samples at home or in local clinics, making clinical trials and pandemic monitoring easier and more accessible.
- What could go wrong
- This was a small, early-phase study in healthy volunteers, so results may not apply to sicker patients. The device may still have issues with sample quality or user errors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Victor Salib
Riverside, California, 92503, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test